Clarus Keeping Commercial Options Open For Oral Testosterone Jatenzo

Jatenzo – the first oral testosterone cleared by US FDA – will compete against injectable and topical formulas in a field that has suffered safety worries in the past. Clarus has a jump on oral rival Lipocine.

Text sign showing Testosterone. Conceptual photo Male hormones development and stimulation sports substance Holding small pitches art papers thoughts ideas memories mat black shadow. - Image

Clarus Therapeutics Inc. has won FDA approval for the first oral formulation of testosterone with the approval of Jatenzo (testosterone udecanoate), a testosterone replacement therapy for certain adult men with conditions associated with a deficiency or absence of endogenous testosterone.

The March 27 approval represents a big milestone for Clarus, coming after a long development road and marking the first...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Deal Watch: Novartis To Develop Cardiovascular Therapies With ProFound

27 Jun 2025

• By Joseph Haas, Sushmita Panda, Jung Won Shin, and Alaric DeArment

Plus deals involving BioCryst/Neopharmed Gentili, Sanofi/Kymera, Abion, Denovo/Chuang Yi, Carisma/OrthoCellix, Otsuka/Harbour Biomed, Aptose/Hanmi, Philochem/RayzeBio, Concentra/Elevation Oncology, and more.